| Symbol | PASG |
|---|---|
| Name | PASSAGE BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2005 MARKET STREET,39TH FLOOR, ONE COMMERCE SQUARE, PHILADELPHIA, Pennsylvania, 19103, United States |
| Telephone | +1 267 866-0311 |
| Fax | — |
| — | |
| Website | https://www.passagebio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001787297 |
| Description | Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Additional info from NASDAQ: |
New Form SCHEDULE 13D - Passage BIO, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0000902664-26-003000 <b>Size:</b> 30 KB
Read moreLynx1 Capital Management LP 🟢 acquired 50.1K shares of Passage BIO, Inc. (PASG) at $4.12 Transaction Date: Jun 25, 2026 | Filing ID: 002945
Read moreNew Form SCHEDULE 13G - Passage BIO, Inc. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0001957912-26-000025 <b>Size:</b> 17 KB
Read morePassage Bio, Inc. - Passage Bio and RemixTherapeutics Announce Merger Agreement
Read moreNew Form 425 - Passage BIO, Inc. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0001104659-26-077350 <b>Size:</b> 36 KB
Read moreNew Form 425 - Passage BIO, Inc. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0001104659-26-077312 <b>Size:</b> 12 MB
Read moreSondhi Dolan 🟢 acquired 10.5K shares (1 derivative) of Passage BIO, Inc. (PASG) at $5.08 Transaction Date: May 19, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04747431 | A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precur… | Phase1 | Frontotemporal Dementia | Active_Not_Recruiting | 2021-09-14 | 2031-08-01 | ClinicalTrials.gov |
| NCT04041102 | Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patien… | — | GM1 Gangliosidosis | Completed | 2020-06-12 | 2024-05-01 | ClinicalTrials.gov |
| NCT04484467 | Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, a… | Na | Irritable Bowel Syndrome | Completed | 2018-02-09 | 2019-12-28 | ClinicalTrials.gov |
| NCT03118154 | Efficacy of Manual Therapy to Improve Quality of Life and Decrease Pain in Subj… | — | Endometriosis | Terminated | 2017-03-31 | 2018-03-31 | ClinicalTrials.gov |
| NCT02639195 | The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL) | — | Small Bowel Obstruction | Unknown | 2015-12-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02027168 | Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women | — | FSH Hypersecretion | Terminated | 2013-02-01 | 2015-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | ACTIVE_NOT_RECRUITING | NCT04747431 |
| CPA | Other | Preclinical | FSH Hypersecretion | TERMINATED | NCT02027168 |
| CPA | Other | Preclinical | FSH Hypersecretion | TERMINATED | NCT02027168 |
| Treatment | Drug | Preclinical | Small Bowel Obstruction | UNKNOWN | NCT02639195 |
| Treatment | Drug | Preclinical | Small Bowel Obstruction | UNKNOWN | NCT02639195 |
| Manual Physical Therapy | Drug | Preclinical | Endometriosis | TERMINATED | NCT03118154 |
| Manual Physical Therapy | Drug | Preclinical | Endometriosis | TERMINATED | NCT03118154 |
| Placebo | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT04484467 |
| Food Supplement With Standardized Menthol, Limonene, and Ginger | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT04484467 |
| Placebo | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT04484467 |
| Food Supplement With Standardized Menthol, Limonene, and Ginger | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT04484467 |
| PBFT02 | Other | Phase PHASE1 | Frontotemporal Dementia | RECRUITING | NCT04747431 |
| PBFT02 | DRUG | Phase PHASE1 | Frontotemporal Dementia | RECRUITING | NCT04747431 |